Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valrubicin.

S V Onrust1, H M Lamb

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|August 25, 1999
PubMed
Summary
This summary is machine-generated.

Valrubicin, a doxorubicin derivative, shows promise for bladder cancer treatment. Intravesical administration demonstrated efficacy in complete response rates for various bladder cancer types with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Denileukin diftitox.

American journal of clinical dermatology·2001
Same author

Perospirone.

CNS drugs·2001
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Valrubicin (AD-32) is a derivative of doxorubicin, an anthracycline with antineoplastic properties.
  • Its mechanism of action is likely through interference with nucleic acid metabolism.
  • Valrubicin exhibits enhanced cellular uptake compared to doxorubicin in vitro.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravesical valrubicin for bladder cancer treatment.
  • To assess response rates in patients with carcinoma in situ and recurrent superficial papillary tumors.
  • To determine the systemic absorption and toxicity profile of intravesical valrubicin.

Main Methods:

  • Non-comparative clinical trials involving intravesical administration of valrubicin.
  • Evaluation of complete response rates in patients with refractory carcinoma in situ and superficial papillary tumors.

Related Experiment Videos

  • Monitoring of adverse events, including bladder irritation and systemic toxicity.
  • Assessment of systemic absorption and comparative toxicity studies in preclinical models.

    • Main Results:

    • Complete response rates of 18% and 29% were observed in patients with carcinoma in situ refractory to intravesical BCG.
    • A 46% complete response rate was achieved in patients with recurrent superficial papillary tumors.
    • Intravesical valrubicin demonstrated minimal systemic absorption, with systemic adverse events in less than 5% of patients.
    • Bladder irritation was the most common adverse event (88%), generally transient.
    • Valrubicin showed reduced toxicity to chick embryos and hematopoietic stem cells in vitro, and lower cardiotoxicity in rabbits compared to doxorubicin.

    Conclusions:

    • Intravesical valrubicin is an effective treatment option for certain types of bladder cancer, including refractory carcinoma in situ and superficial papillary tumors.
    • The drug is generally well-tolerated when administered intravesically, with predominantly local side effects and minimal systemic absorption.
    • Valrubicin presents a potentially favorable safety profile compared to doxorubicin, particularly concerning cardiotoxicity.